Simcere Pharmaceutical Group (HKG:2096) said its oncology drug Enzeshu has been added to China's 2025 National Reimbursement Drug List, according to a Monday Hong Kong bourse filing.
The update, effective Jan. 1, 2026, also includes a renewal of Endostar, which has remained on the list since 2017, the filing said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.